During the pandemic years, Decentralized Clinical Trials (DCTs) were presented as the inevitable future of clinical research. Telemedicine, eConsent, wearable devices, direct-to-patient drug delivery, and remote monitoring seemed to announce the end of the traditional site-based clinical trial model.
A few years later, the industry reality is far more nuanced.
DCTs have not disappeared. But neither have they replaced traditional trials. Instead, the industry has entered a phase of maturity, where the initial excitement has been replaced by a more pragmatic question: what actually works?
One of the most important lessons from recent years is that fully virtual models remain the exception. Most sponsors and CROs are now adopting hybrid models, where some activities are decentralized while others remain site-based.
For example:
This “fit-for-purpose” approach helps reduce patient burden without compromising operational control or data quality.
The industry has realized that decentralization is not a goal in itself. It is simply a tool.
Several DCT benefits have remained strong even after the hype cycle faded.
For patients living in remote areas or those with limited mobility, remote visits and digital monitoring significantly reduce participation barriers.
Many operational teams report that DCTs work better as a retention tool than as a primary recruitment mechanism. Fewer site visits often translate into lower patient dropout rates.
Wearables and connected devices enable continuous data collection and provide insights closer to real-world evidence.
DCTs accelerated the industry’s transition toward more patient-centric trial models — a change that will likely remain permanent in clinical research.
At the same time, many early promises encountered difficult operational realities.
One of the most common challenges remains “technology overload.” Sites and patients are often required to use multiple disconnected platforms: ePRO, eConsent, telehealth, wearables, portals, and logistics systems.
The result?
More operational complexity, additional training requirements, and a higher risk of errors.
Not all patients are comfortable with technology. In certain indications — especially elderly populations — fully remote models created major recruitment and compliance challenges.
Initially, many expected DCTs to reduce trial costs. In practice, implementing digital infrastructure, integrating systems, and managing logistics increased costs for many studies.
Although regulatory authorities support decentralized elements, expectations around quality oversight, data integrity, and patient safety remain just as strict.
The term “Decentralized Clinical Trial” itself may gradually become less relevant. The reason is simple: many DCT elements have already become standard components of modern clinical trials.
Today, the question is no longer:
“Are we running a DCT?”
But rather:
“Which decentralized components deliver real value for this protocol and this patient population?”
The future likely belongs to:
After the hype, the industry is left with something far more valuable: a more mature, realistic, and sustainable approach to innovation in clinical research.